Aberrant crypt foci: The case for inclusion as a biomarker for colon cancer

Michael J. Wargovich, Vondina R. Brown, Jay Morris

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


Aberrant crypt foci (ACF) are one of the earliest histopathological manifestations of colon cancer. In this review, we critically present the molecular, cellular, histopathological, and chemopreventive evidence that ACF are relevant biomarkers for colon cancer. The laboratory and clinical evidence are highly suggestive that ACF are in the pathway leading to colon cancer, but not all ACF will do so. The possible fate and outcome of ACF in the progression toward colon cancer may be dependent on a number of features that define their predictive power for the prevention or progression of cancer.

Original languageEnglish (US)
Pages (from-to)1705-1716
Number of pages12
Issue number3
StatePublished - Sep 2010
Externally publishedYes


  • Aberrant crypt foci
  • Biomarker
  • Chemoprevention
  • Colon cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Aberrant crypt foci: The case for inclusion as a biomarker for colon cancer'. Together they form a unique fingerprint.

Cite this